InflaRx N.V. is a clinical-stage biopharmaceutical company focused on inflammatory disease therapeutics, currently advancing candidates vilobelimab and izicopan through clinical trials. Despite consistent net losses exceeding €45 million annually and minimal revenue contribution, the company sustains operations through equity financing and government grants. Recent Nasdaq minimum bid price notices underscore market valuation challenges, while clinical progress and regulatory milestones in Phase 2b trials for hidradenitis suppurativa remain critical to future viability. InflaRx's capital allocation reflects ongoing R&D investment with limited operational cash flow, emphasizing reliance on equity raises amidst potential dilution.